Industry news that matters to you.  Learn more

BGI Expanding Proteomics Services to Include Mass Spectrometry

Earlier this month, Adam Bonislawski at GenomeWeb’s Proteomonitor reported that China-based BGI intends to expand its proteomics offerings and buy ~50 new mass spectrometers over the next two years. This diversification into clinical and drug-development services is a forward-thinking move for the genomics/bioinformatics giant and one that should be taken seriously by current proteomics service providers.

Aushon’s Multiplex Immunoassay Platform Used to Validate Panel of Prognostic and Predictive Protein Biomarkers in Recent Phase II and Phase III Studies

Data was presented at the recent American Society of Clinical Oncology’s 2011 Genitourinary Cancers Symposium showing multiple protein biomarkers predictive of clinical benefit and prognostic of disease outcome in patients with advanced or metastatic renal cell cancer.

Boston Microfluidics Contracts Affinity Life Sciences for Immunoassay Development and Protein Chemistry Services

Boston Microfluidics, Inc. (BMF), a developer of a novel Point-of-Care (POC) device, and Affinity Life Sciences, Inc., a contract research and manufacturing organization specializing in biomarker assay development and protein chemistry services, have partnered to develop immunoassays and chemistry components related to Boston Microfluidics’ POC device.

Plasma von Willebrand Factor a Biomarker for Risk of Adverse Events in Anticoagulated Atrial Fibrillation Patients

In patients with atrial fibrillation (AF) who were anticoagulated, plasma levels of von Willebrand factor (VWF) were found to be an independent risk factor for adverse events, including cardiovascular mortality and major bleeding. The study is published in the April 13th online edition of the Journal of the American College of Cardiology.

Aushon LaunchesNew SignaturePLUS System for Multiplex Protein Biomarker Analysis

Aushon announced today the global launch of its next generation SignaturePLUS Imaging and Analysis System. The SignaturePLUS system is designed to meet the cost and performance needs of researchers for accurate, reproducible, and reliable multiplex protein biomarker analysis across pre-clinical, clinical and diagnostics applications in all therapeutic areas.